Astellas Pharma, Nippon Boehringer Ingelheim Seek Additional Approval for Micardis.Tokyo, Japan, July 5, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Astellas Pharma Astellas Pharma Inc. (アステラス製薬株式会社 and Nippon Boehringer Ingelheim have filed a joint application for an additional indication of Micardis, an angiotensin II angiotensin II n. An octapeptide that is a potent vasopressor and a powerful stimulus for production and release of aldosterone from the adrenal cortex. receptor blocker, with the Ministry of Health, Labor and Welfare. The two companies expect that Micardis will become applicable for the treatment of type 2 diabetic nephropathy diabetic nephropathy (n  fro´p . For this application, they have submitted clinical data from INNOVATION, a large-scale clinical study conducted in Japan from January 2003 to November 2006. Micardis, which is manufactured by Nippon Boehringer Ingelheim and sold by Astellas Pharma in Japan, is currently indicated for the treatment of hypertension. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion